0B68 Chapman, Andrew - Thomas Jefferson University - Thomas Jefferson University
Dr. Chapman

Andrew Chapman, DO, FACP

Contact Dr. Chapman

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 923-5676

Most Recent Peer-reviewed Publications

  1. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eas 1C84 tern Cooperative Oncology Group Study
  2. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
  3. Reply to M.-E. Rougé Bugat et al
  4. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research
  5. Comorbidity in older adults with cancer
  6. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer
  7. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer
  8. Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors
  9. Erratum: Silver oncologic tsunami: Quality issues in the senior adult oncology population (Journal of Oncology Practice (2015) 11, (190-192))
  10. Silver oncologic tsunami: Quality issues in the senior adult oncology population
  11. Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience
  12. Senior adult oncology: Three cases of advanced cancer in patients of advanced age
  13. Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts
  14. Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy
  15. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy
  16. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance
  17. Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer
  18. Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma
  19. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine
0